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Abstract
Surgical site infection is a common cause of post-operative morbidity, often leading to implant 
loosening, ultimately requiring revision surgery, increased costs and worse surgical outcomes. 
Since implant failure starts at the implant surface, creating and controlling the bio-material 
interface will play a critical role in reducing infection while improving host cell-to-implant 
interaction. Here, we engineered a biomimetic interface based upon a chimeric peptide that 
incorporates a titanium binding peptide (TiBP) with an antimicrobial peptide (AMP) into a single 
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mutans and S. epidermidis, two bacteria which are linked with clinical implant infections. To 
optimize antimicrobial activity, we investigated the design of the spacer domain separating the two 
functional domains of the chimeric peptide. Lengthening and changing the amino acid 
composition of the spacer resulted in an improvement of minimum inhibitory concentration by a 
three-fold against S. mutans. Surfaces coated with the chimeric peptide reduced dramatically the 
number of bacteria, with up to a nine-fold reduction for S. mutans and a 48-fold reduction for S. 
epidermidis. Ab initio predictions of antimicrobial activity based on structural features were 
confirmed. Host cell attachment and viability at the biomimetic interface were also improved 
compared to the untreated implant surface. Biomimetic interfaces formed with this chimeric 
peptide offer interminable potential by coupling antimicrobial and improved host cell responses to 
implantable titanium materials, and this peptide based approach can be extended to various 
biomaterials surfaces.
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1. Introduction
Bone and joint implants have revolutionized the healthcare of aging patients whose life 
expectancy has been increasing.1 Implants have been intensively used during the last 40 
years in treating bone and joint degeneration, neoplasms, trauma and inflammation.1 
Titanium and titanium alloys are used as implant biomaterials due to their biocompatibility, 
mechanical strength, and noncorrosive properties.2–5 However, nosocomial microbial 
attachment to the implant surface can result in infection and inflammation with implant 
loosening that requires surgical revision. In the first hours following surgery the implant 
surface is most vulnerable to bacterial colonization and the bacterial pathogens are also most 
susceptible to antimicrobial treatment.6,7 With time, bacteria populations multiply and co-
operate to form biofilms that function as natural barriers against antibiotic effectiveness.8 
Treatment for infection of this type is difficult and the revision surgery is more complex, 
adding to patient morbidity and overall health care costs. Despite improvements in implant 
technology including prophylactic therapy, most implant failures can be attributed to either 
infection or aseptic loosening resulting from poor integration with host tissue.9,10 Failure 
requiring revision surgery is caused by infection in 7.5% of total hip arthroplasty (THA) and 
14.8% of total knee arthroplasty (TKA) and by aseptic loosening in 55.2% of THA and 
29.8% of TKA.11 Immediate prevention of bacterial attachment on the implant surface is 
critical in prevention of infection related failure. However, host cell attachment and viability 
at the interface is also critical to host bone integration to prevent implant loosening. 
Therefore, an imperative clinical need exists to prevent bacterial colonization on the implant 
surface while not negatively affecting host cell response that could lead to poor integration 
of the implant material with the host. An implant surface with a fast-acting, broad-spectrum 
antimicrobial function prevents bacterial attachment to reduce biofilm formation while 
maintaining implant integration with the host tissue would prove to be a paradigm shift.
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Multiple strategies have been developed with the aim of eliminating microbial attachment on 
the implant surface. Among them, the use of antibiotics have been commonly employed in 
daily practice as of today. For example, vancomycin powder is commonly used in posterior 
spinal wounds and has been shown to decrease surgical site infection. However, the rise of 
antibiotic resistance is lately becoming a major concern in dealing with bacteria, which also 
led to an increase in efforts to find alternative strategies.2–5 Silver, polyethylene glycol 
(PEG), or quaternary ammonia-based compounds (QACs) have been among the well-studied 
examples to bring the antimicrobial property by attaching them to the biomaterials using 
covalent chemical bonds.12–17 Another strategy is to improve the antibacterial properties of 
metals by doping them with elements such as bismuth and zinc.18,19 While promising, 
chemistry based immobilizations require complex steps, which may be not favorable within 
biological environment due to their harshness. Additionally, uniform coatings where 
bioactivity is both preserved and homogenously distributed throughout the biomaterial 
surface following their coupling onto the biomaterials are challenging to obtain.
Another infection prevention strategy is to coat the implant surface with antimicrobial 
peptides (AMPs). AMPs are abundant in nature and employed as natural innate immune 
system defense fighters. AMPs are fast-acting antimicrobial agents that are effective against 
a broad spectrum of gram-positive bacteria, gram-negative bacteria, viruses and fungi.20–22 
AMPs offer an alternative to conventional antibiotics to which some pathogens develop 
resistance more readily.23 However, with the current technologies available, AMPs can be 
covalently immobilized onto the implant surfaces, but covalent immobilization of 
biomolecules has also proven to be less effective due to lack of control over the 
conformation of the biomolecules, which is critical to preserve their biofunctionality. In our 
previous studies, we demonstrated that AMPs can be immobilized on titanium implant 
surfaces through the engineering of chimeric peptides that use molecular recognition to 
attach and self-assemble on the implant surface as a novel biomolecular-coating.24–26 A 
chimeric peptide is a bifunctional single-chain relatively short peptide when compared to 
biological proteins, and it joins two functional domains through an engineered spacer. The 
functional domain joined to the AMP for immobilization on implant surface is a peptide that 
is identified using combinatorial biology based molecular libraries, i.e., phage and cell 
surface display libraries. These genome based screening process of the peptides allows to 
discovery of the potential candidates that can interact with the solid materials building upon 
molecular recognition, a feature found similar to Nature. Due to phenotype-genotype-based 
relations obtained for inorganic materials throughout the combinatorial biology-based 
selection process, these peptides are generally referred as genetically engineered peptide for 
inorganics (GEPIs). GEPIs offer the ability to use molecular recognition to self-assemble 
active peptide-based agents selectively on inorganic materials including titanium 
implants.27,28 Previous work has identified several titanium binding peptides (TiBP) that 
assemble onto the titanium surface with high affinity appropriate for the surface of titanium 
and titanium alloy-based implants.24,25 Peptide-based self-immobilization strategies 
therefore offer an opportunity to overcome the limitations and challenges associated with 
covalent immobilization of antibacterial agents on implant surfaces.
The current paper builds upon our studies suggesting that the function of an engineered 
chimeric peptide can be further improved through a spacer region that is placed in between 
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the individual functional domains, i.e., TiBP and AMP. The novel design employed here 
allows the retention of AMP secondary structural features responsible for the antimicrobial 
activity without jeopardizing the implant self-assembling domain of the peptide. The 
changes offered in the spacer design induce enough structural alterations in the chimeric 
peptide to be more effectively displayed at the bio-materials interfaces. Herein, we 
demonstrate that engineering the length and composition of the spacer lead to improved 
antimicrobial function and favorable host cell response. Chimeric peptides offer a simple 
unifying strategy to immobilize AMPs as a uniform biocoating on titanium implant surfaces 
to combat implant failure due to infection.
2. Experimental Methods
2.1. Chimeric peptide design
TiBP and AMP domains previously demonstrated as viable in a chimeric peptide (TiBP-
Spacer3-AMP) were selected for this work.24 Briefly, TiBP was selected by screening a 
bacterial surface display system, FliTrx (Invitrogen, Carlsbad, CA) against a titanium 
surface.27–29 After four rounds of bio-panning, 60 clones were selected and characterized 
based on their surface binding affinity using fluorescence microscopy techniques. The 
strongest binding sequence determined through these experiments was used in our chimeric 
peptide to bind to the titanium surface, anchoring the chimeric peptide. The AMP domain 
used in our chimeric peptide was computationally designed by data mining the available 
library of peptides.25,30,31 A novel spacer, Spacer5 was designed as an elongated link, 
joining TiBP with AMP to form the chimeric peptide, TiBP-Spacer5-AMP. TiBP-Spacer5-
AMP was synthesized using solid phase peptide synthesis by KanPro (Lawrence, KS). 
Physical chemical data including, molecular weight, isoelectric point, charge and GRand 
AVerage of hydropathY (GRAVY) scores based on amino acid sequences for AMP, TiBP, 
TiBP-Spacer3-AMP, and TiBP-Spacer5-AMP were obtained using the ExPasy Proteonomics 
Server.32
2.2. Molecular structure modeling
To understand how the secondary structure of the chimeric peptides change in solution 
depending on the spacer sequence, we generated ensembles of 1,000 likely structures using 
the PyRosetta project software and identified secondary structures with the DSSP 
program.33,34 Structure generation is stochastic using a knowledge-based energy scoring 
function. An ensemble of structures was generated for each full chimeric peptide and each 
peptide domain to sample likely structural variations. Ramachandran plots were generated 
for the lowest energy structures for TiBP-Spacer3-AMP and TiBP-Spacer5-AMP structures. 
Chimera Software version 1.9 from University of California at San Francisco was used to 
visualize the structures.35
2.3. Antimicrobial “rule induction” method
A “rule induction” method was used to correlate the generated secondary structures with the 
probability of antimicrobial function. Rule induction is a data mining approach to learn 
associations between paired sets of data made of sets of cases. As previously published, our 
paired data is the computationally generated structure decoys for both chimeric AMPs and 
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AMPs paired with the minimum inhibitory concentration (MIC) of the peptides in 
solution.1,24 Each structural decoy represents a single case in a set of cases. Given a list of 
cases where each case has a list of features and a selected outcome, rough-set theory 
approaches rule induction by looking for features which apply to the maximum number of 
cases and are selective for the selected outcome.36 For our project, the cases are structure 
decoys and the list of features are the secondary structure features found. The paired distinct 
outcome is the MIC result from the in-solution assay. The rough set theory implementation 
is based on MLEM2.37 Two secondary structure features, 4-amino-acid right-handed alpha 
helices and 5-amino-acid alpha helices were key features for rules inducted from our 
previous work.24 These rules associated with strong antimicrobial activity for the bacteria 
tested (S. epidermidis and S. mutans). The secondary structure feature frequencies of these 
two rules were compared against TiBP-Spacer3-AMP and TiBP-Spacer5-AMP. Higher 
frequencies of these secondary structure features associate with stronger antimicrobial 
activity.
2.4. Circular dichroism (CD) analysis
A solution containing 50 μM TiBP-Spacer5-AMP in phosphate buffered saline (PBS) at pH 
7.4 was prepared for circular dichroism (CD) analysis. The spectrum is the average of four 
scans from 190–239 nm using a Jasco J-810 spectrometer (Easton, MD). Appropriate 
background buffer subtraction was performed and the instrument carefully calibrated. The 
averaged spectrum was subtracted from background and smoothed with the Savitzky–Golay 
algorithm. The spectrum was transformed for mean residue ellipticity in degrees · cm2/dmol. 
Two methods were used to estimate the secondary structure features from the CD spectra. 
The CAPITO method makes a comparison to reference spectra for helix (α-helix, 310-helix 
and π-helix), β-strands (β-sheets, β-bridge) and irregular secondary structures (bonded 
turns, bends and loops) using a liner regression method.38 The Raussens method is a 
concentration-independent estimation of α-helix, β-sheets and irregular secondary structure 
proportions.39
2.5. Bacterial maintenance and culturing
The antimicrobial activity of TiBP-Spacer5-AMP was evaluated against two bacterial 
strains, S. mutans (American Type Culture Collection (ATCC) 25175, Manassas, VA) and S. 
epidermidis (ATCC 29886). S. mutans cultures were prepared using Brain Heart Infusion 
Broth (BHI, BD Difco, Franklin Lakes, NJ) and S. epidermidis using Nutrient Broth (NB, 
BD Difco) according to ATCC protocols. Bacterial pellets obtained from ATCC were 
rehydrated in appropriate media of which several drops were used to streak either BHI or 
NB agar plates. Bacteria streaked agar plates were subsequently incubated for 24 h. Agar 
plates and cultures were incubated at 37°C in the presence of 5% CO2-supplemented 
atmosphere for S. mutans and in aerobic atmosphere and 200 rpm shaking for S. 
epidermidis. Overnight cultures were made by aseptically transferring a single-colony 
forming unit (CFU) into 10 mL of appropriate broth media followed by incubation in 
appropriate conditions for 16 h. Bacteria from overnight cultures were used to inoculate 
fresh media and grown to mid-log phase.
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2.6. Antimicrobial activity in solution
The MIC of TiBP-Spacer5-AMP against S. mutans and S. epidermidis in solution was 
evaluated in 96 well plates (Corning Costar 3370, Corning, NY) spectrophotometrically over 
a period of 24 h by obtaining a measurement for the optical density at 600 nm (OD600) every 
two hours. Optical density at 600 nm was measured using a Cytation3 microplate reader 
(Bio Tek Instruments, Winooski, VT). Bacteria grown to mid-log phase at a density of 107 
CFU/mL were cultured at appropriate growth conditions in appropriate broth media only as 
a control or in broth media containing a range from 5–70 μM of TiBP-Spacer5-AMP for S. 
mutans and 1-10 μM for S. epidermidis. The OD600 measurements obtained, relating optical 
density to bacteria CFUs/mL, were plotted versus time to generate standard growth curves. 
The minimum concentration of TiBP-Spacer5-AMP at which no increase in optical density 
measurement, corresponding to no bacterial growth occurring was designated as the MIC. 
AlamarBlue assay (Invitrogen, Carlsbad, CA) was used for determination of a minimum 
bactericidal concentration of TiBP-Spacer5-AMP. Bacteria in broth media only and with the 
TiBP-Spacer5-AMP concentrations described in the MIC experiments were prepared in 96 
well plates. AlamarBlue reagent was added to experimental wells and incubated for two 
hours at 37°C. Experimental wells were observed and evaluated for color change. Wells 
corresponding to concentrations of TiBP-Spacer5-AMP where no color change occurred 
were determined to have bactericidal concentrations of the chimeric peptide.
2.7. Titanium surface preparation
Two surfaces, 99% pure titanium foil (Alfa Aesar 43677, Ward Hill, MA) and titanium 
implant discs cut from standard rods used in posterior lumbar surgery (University of Kansas 
Medical Center Department of Neurosurgery, Kansas City, KS) were used for evaluation of 
TiBP-Spacer5-AMP bio-coating antimicrobial activity. Titanium foils were cut into squares 
measuring 0.5 mm thick × 1 cm × 1 cm and 6 mm diameter implant rods were cut by the 
University of Kansas Medical Center Department of Neurosurgery with a standard 
orthopedic surgical rod cutter into 3 mm long disc segments. Surfaces were sterilized by 
soaking overnight in 70% bleach, followed by sonication for 15 min in each 1:1 
acetone:methanol, isopropanol and filtered deionized water, dried under UV light in a 
biosafety cabinet and then autoclaved.
2.8. Chimeric peptide coating on surfaces
Sterilized titanium surfaces were transferred to sterile 24 well plates (Costar 3738) with the 
bactericidal concentrations (60 μM for S. mutans and 10 μM for S. epidermidis) of TiBP-
Spacer5-AMP dissolved in PBS at pH 7.4 and incubated at 37°C, constant agitation (200 
rpm) for 4 h.24 Following incubation substrates were washed twice by pipetting with PBS to 
remove unbound peptide and transferred to sterile 24 well plates to be used in experiments.
2.9. Antimicrobial activity on substrates
Antimicrobial activity of TiBP-Spacer5-AMP bio-coated titanium surfaces against each 
bacterial strain was evaluated by culturing bacteria in 24 well plates containing bio-coated 
surfaces or bare, untreated control surfaces. Bacteria grown to mid-log phase at a 
concentration of 107 CFU/mL were harvested by centrifugation at 2000 × g for 5 min 
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followed by resuspension in 500 μL of appropriate media, transferred to sterile 2 mL 
centrifuge tubes, and then centrifuged at 2000 × g for three minutes.24 The supernatant was 
carefully removed from the pellet and the pellet resuspended in PBS at final concentration of 
108 CFU/mL and 500 μL of suspension was added to wells containing foil surfaces and 1000 
μL to wells with implants. Well plates with TiBP-Spacer5-AMP bio-coated surfaces were 
incubated for two hours at 37°C in the presence of 5% CO2-supplemented atmosphere for S. 
mutans and in aerobic atmosphere and 200 rpm shaking for S. epidermidis. Following 
incubation all surfaces were washed with PBS to remove unbound bacteria. Bacteria were 
fixed with 1 mL of 2% glutaraldehyde solution for 30 min and then dehydrated in 50%, 
70%, 90% and 100% ethanol baths, 10 min for each ethanol concentration. Bacteria were 
stained with SYTO 9 green fluorescent dye (Life Technologies L7012, Carlsbad, CA), 
incubated for 15 min at room temperature protected from light and excess dye was removed 
by washing twice with PBS. Stained bacteria were imaged with a fluorescence microscope 
(Olympus Spin Disk Epifluorescent microscope, Richmond Hill, Ontario, Canada) at an 
excitation/emission wave number provided by the manufacturer. Five representative 
fluorescence images were taken for each sample (n = 3) and the bacteria were quantified 
using ImageJ Software and then subjected to statistical analysis.
2.10. Host cell response
Host cell response was evaluated with a fibroblast cell line (NIH/3T3 ATCC CRL-1658). 
The fibroblast cells were cultured following the ATCC protocol. Briefly, cells were grown in 
DMEM media (Gibco 11995073, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(Gibco 10437036) and 1% penicillin-streptomycin (Gibco 15070063) and incubated at 37°C 
in a 5% CO2 atmosphere. Fibroblasts were passaged using 0.25% Trypsin-EDTA (Gibco 
25200072) and cells were counted to ensure correct seeding concentrations.
Fibroblast cell response to 60 μM TiBP-Spacer5-AMP bio-coating, 200 μg/mL collagen 
(Sigma C7661, St. Louis, MO) coating (positive control) and bare, untreated (negative 
control) titanium foil and implant surfaces was studied. Fibroblast cells at a concentration of 
8 × 105 cells/mL were added to sterile 24 well plates containing TiBP-Spacer5-AMP coated, 
collagen coated, or bare, untreated foils or implants and incubated for 24 h at 37°C in a 5% 
CO2 atmosphere. Fibroblast attachment and spreading were evaluated by fixing fibroblasts 
on titanium surfaces with 2% glutaraldehyde solution, followed by dehydration in 10%, 
30%, 60%, 90% and 100% ethanol. Fixed fibroblasts on titanium surfaces were washed 
twice with PBS, permeabilized with TritonX (Sigma T8787), sealed with BSA (Fisher 
BioReagents BP671-10, Carlsbad, CA), and stained with Alexa Fluor488-Phalloidin dye 
(Invitrogen). Unbound dye was removed by washing with PBS and substrates were imaged 
with a fluorescent microscope at 4, 10 and 20 times magnification. Five representative 
images of each surface (n = 3) were obtained and analyzed with ImageJ Software and then 
subjected to statistical analysis. Cell attachment was determined as number of cells per 
square millimeter and the percentage of the image surface covered by attached cells. 
Another measure of viability, metabolic activity was determined using a MTT (3-(4,5-
dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) assay (Sigma M5655). Following 
incubation of fibroblasts with TiBP-Spacer5-AMP, collagen, or bare, untreated titanium 
surfaces for 24 h at 37°C in a 5% CO2 atmosphere, one tenth of the well liquid volume was 
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removed and replaced by the same volume of 5 mg/mL MTT reagent. The substrates with 
MTT reagent were incubated for 3 h then transferred to a sterile 24 well plate. The formazan 
crystals were dissolved in the detergent reagent according to the manufacture's protocol. 
Absorbance was measured at 570 nm.
3. Results and Discussion
Here, we engineered and evaluated a chimeric peptide composed of a titanium binding and 
an antimicrobial domain linked by a novel spacer design (TiBP-Spacer5-AMP). Our 
objective was to preserve the secondary structural features of both the TiBP and the AMP so 
as to impart an effective antimicrobial activity against two bacteria commonly associated 
with nosocomial implant infections, S. mutans and S. epidermidis.40,41 Data from a similar 
chimeric peptide with identical functional domains, but a shorter spacer sequence (TiBP-
Spacer3-AMP) and the AMP peptide alone were used to evaluate the effect of the new 
engineered spacer design.24–26 Table 1 contains the sequences and physical chemical 
properties for each chimeric peptide and their functional domains. Despite the physical 
chemical similarity to one another, we observed improved antimicrobial activity with the 
altered amino acid composition designed into the longer spacer called Spacer5. The 
interfacial activity model suggests that antimicrobial activity depends on amino acid 
composition and physical chemical properties.42 Interfacial activity is the electrostatic and 
hydrophobic interactions between peptides and the lipid surface of the bacterial cell wall. 
Literature suggests several mechanisms leading to cell death following interaction between 
the peptide and the lipid surface including a compromised bacterial cell wall which initiates 
a cascade of effects including cellular respiration, DNA damage and altered gene expression. 
Recent publications indicate the production of reactive oxygen species (ROS) when AMPs 
attack bacteria.43–45 Much of the literature characterize AMP activity based on either 
structure-function relationships or physical chemical properties.42 The effect of the 
engineered spacer design was evaluated through independent, but corroborating approaches, 
including: computational and direct structural analysis coupled with measurement of 
antimicrobial activity of the chimeric peptide in solution, as well as when bound to titanium 
substrates against common nosocomial microorganisms allowing us to suggest that the 
restored antimicrobial activity is due to the preserved structure associated with the Spacer5 
design.
3.1. Computational structure and function predictions
Computational molecular structures were generated using the PyRosetta structural ensemble 
generation method.33 One thousand likely energy minimized structures were generated for 
each chimeric peptide, for each spacer sequence, and for each functional domain. The lowest 
energy structure for each is depicted in Fig. 1 with TiBP, spacer domain, and AMP 
designated with blue-, black-, and red-shading, respectively. The images shown in Fig. 1 
represent likely structures that are modeled in solution. Ramachandran plots were generated 
for the lowest energy chimeric peptide structures and are shown in the supporting 
information as Figs. S1 and S2 for TiBP-Spacer3-AMP and TiBP-Spacer5-AMP, 
respectively. The Ramachandran plots simulates the contribution of hydrogen bonding 
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among backbone atoms and can be interpreted to correlate the contribution of the α-helix or 
β-sheet structural features depicted in the energy minimized structures.
Previous published analysis using the “rule induction method” suggest that increasing the 
number of short α-helices is associated with antimicrobial activity, therefore we first 
examined the structure of the chimeric peptides.24 The computational structures in Fig. 1 
show the secondary structure features for the chimeric peptides and their component parts. 
The structure of both TiBP and AMP peptides show features of alpha helicity with a stronger 
helicity prominence in the AMP domain [Fig. 1(e)]. TiBP-Spacer3-AMP [Fig. 1(a)], has an 
α-helix feature beginning within the AMP domain and preserved through Spacer3. From the 
Ramachandran plot we conclude the α-helix feature is approximately 26 amino acids long 
and confirm that backbone angles consistent with α-helix features are present though AMP, 
Spacer3, and almost the entire TiBP. All but three amino acids correspond to psi/phi angles 
(−90°, −60°) consistent with α-helix. Spacer3 consists of but three glycine amino acid 
residues; therefore the minimal side chain size of glycine in Spacer3 could allow the alpha 
helix feature to be preserved across the spacer domain and into the TiBP, producing longer 
alpha helices. The alpha helix feature in TiBP-Spacer5-AMP is comparatively much shorter. 
The Ramachandran plot for TiBP-Spacer5-AMP shows the psi/phi angles (−90°, −60°) 
corresponding to alpha helicity are assigned to the AMP domain, while psi/phi angles (−90°, 
+120°) corresponding to β-sheet/random coil secondary structures are observed in the rest of 
the molecule. We interpret these finding to suggest that the Spacer5 segregates the AMP 
domain from the rest of the chimeric peptide, allowing its antimicrobial activity to be 
preserved.
The Spacer5 (GSGGG) is composed of four glycine and a single serine amino acid residues, 
and the presence of a polar serine residue could produce a slight “ST staple” feature in the 
spacer region producing a backbone bend that prevents the continuity of the alpha helix 
feature observed in TiBP-Spacer3-AMP. The α-helix property that most accurately predicts 
antimicrobial activity by the “rule induction method” against S. mutans and S. epidermidis is 
the number of five amino acid- and four amino acid-right-handed-helices. The “rule 
induction method” also predicts antimicrobial function based on the percentage of these 
features present in the energy minimized PyRosetta generated structures. The “rule induction 
method” was used to predict the antimicrobial activity of TiBP-Spacer5-AMP and TiBP-
Spacer3-AMP with the results shown in Table 2. Of the 1000 structures generated in the 
ensembles for each chimeric peptide, TiBP-Spacer5-AMP had a larger percentage of 
structural topologies represented with four or five amino acid residue alpha helix features. 
This is consistent with what we observed with the detailed structure analysis conducted for 
the lowest energy structure of each chimeric peptide. Based on previously published data 
validating the “rule induction method”, we predict that TiBP-Spacer5-AMP should have 
greater antimicrobial activity in solution against S. mutans and S. epidermidis.24 To further 
corroborate our analysis, we next turned to CD analysis which can directly measure 
secondary structure of TiBP-Spacer5-AMP.
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3.2. Structure determination with CD
The chimeric peptide was prepared at a concentration of 50 μM in PBS at pH of 7.4 for 
secondary structure analysis by CD. Two complementary methods, the CAPITO and the 
Raussens method were used to quantify the results obtained from the CD spectra.38,39 We 
applied both the concentration dependent CAPITO method and the concentration 
independent Raussens method for these predictions to corroborate outcomes. Both 
approaches are regression methods used to transform CD spectral data in order to identify 
corresponding structural information from a protein database. The CD spectrum for TiBP-
Spacer5-AMP is depicted in Fig. 2 with inset table containing results from analysis with the 
regression methods. The spectrum for the chimeric peptide with Spacer5 indicates a greater 
preference for right-circularly polarized light absorbance compared to the previously 
published spectrum for Spacer3, indicating that the predominance of α-helix secondary 
structure present in TiBP-Spacer3-AMP is not preserved through the newly designed 
Spacer5.26 The CD structural prediction results are consistent with the computationally 
predicted secondary structure analysis, indicating that a majority of the secondary structure 
of TiBP-Spacer5-AMP is β-sheet or random coil. Moreover, both the CAPITO and Raussens 
method assigns 86% and 55% secondary structure to irregular or random coil features, for 
TiBP-Spacer5-AMP, respectively. In addition to random coil features, the Raussens method 
assigns 38% of TiBP-Spacer5-AMP secondary structure to beta sheet features. The Raussens 
method also corroborates the Ramachandran plot prediction for analysis computationally 
generated structures. These secondary structure features are predicted by the “rule induction 
method” to also produce a greater antimicrobial activity for TiBP-Spacer5-AMP. These 
structural analyses are related only to the in solution secondary structure of the chimeric 
peptides not their structures when bound to titanium surfaces. Currently, a computational 
model for proteins bound to a titanium surface does not exist. While this limits our ability to 
describe the exact structural contributions to antimicrobial activity on the titanium implant 
surface, we can however measure the antimicrobial activity of the chimeric peptides in 
solution and empirically apply those findings to titanium surfaces.
3.3. Chimeric peptide function
3.3.1. Antimicrobial effect in solution—Antimicrobial activity in solution was 
elucidated by determining the MIC of TiBP-Spacer5-AMP required to inhibit growth for 
two bacterial strains commonly recovered from infected implants, S. mutans and S. 
epidermidis.40,41 Previously published MIC values for TiBP-Spacer3-AMP and AMP alone 
were used for comparison.24 MIC data for AMP, TiBP-Spacer3-AMP, and TiBP-Spacer5-
AMP are depicted in Table 3. The MIC value of TiBP-Spacer5-AMP against S. mutans and 
S. epidermidis are 50 μM and 8 μM, respectively. We observed a remarkable three fold 
improvement of MIC antimicrobial activity for the TiBP-Spacer5-AMP against S. mutans. 
This can be attributed to the increased frequency of secondary structural features 
corresponding to antimicrobial activity as predicted by the “rule induction method”, 
corroborating the importance of secondary structure features in AMP design. The design of 
the spacer offers an opportunity to fine-tune the structural properties of the chimeric peptide 
so as to improve its antimicrobial potential. The use of the Spacer5 results in a chimeric 
peptide displaying shorter α-helix structural features compared to Spacer3 and yields 
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improved antimicrobial activity. In contrast however, the antimicrobial activity of TiBP-
Spacer5-AMP against S. epidermidis appears to be slightly diminished compared to TiBP-
Spacer3-AMP. We cannot yet account for why TiBP-Spacer5-AMP was less effective 
against S. epidermidis, than S. mutans and we are conducting further experiments to 
investigate this observation.
The bactericidal concentration for TiBP-Spacer5-AMP against each bacteria was also 
determined using the AlamarBlue assay.46 The bactericidal concentration for TiBP-Spacer5-
AMP was found to be 60 μM for S. mutans and 10 μM for S. epidermidis. These 
concentrations are only slightly higher than the observed MIC values indicating that TiBP-
Spacer5-AMP corroborating these complementary methods of killing bacteria. Next, we 
used the bactericidal concentrations determined from the AlamarBlue assay to assess the 
antimicrobial activity of medical implants coated with TiBP-Spacer5-AMP by assessing 
bacterial growth on their surfaces.
3.3.2. Antimicrobial effect on surfaces—TiBP-Spacer5-AMP at 60 μM for S. mutans 
and 10 μM for S. epidermidis were permitted to self-assemble on selected titanium surfaces 
and evaluated for their antimicrobial activity. Titanium foils were selected for their ease of 
use, while discs cut from stock titanium orthopedic bar material were used to ascertain their 
effectiveness directly on a clinically relevant surface. For both surfaces, infectious organisms 
common to clinical infections, S. mutans and S. epidermids, were used to evaluate the 
antimicrobial activity of the bio-coating. Previous studies had established the binding 
characteristics and affinity for the TiBP as part of a chimeric molecule.24 Following 
incubation, the unbound peptide was removed by repeated washing, suggesting the 
antimicrobial activity observed for either titanium surface was the result of the chimeric 
peptide bound to the surface representing antimicrobial activity. The observed effectiveness 
of TiBP-Spacer5-AMP antimicrobial effect against S. mutans is shown in Fig. 3 and against 
S. epidermidis in Fig. 4. The images are representative areas, and the percent of the total 
surface area covered by bound bacteria was identified by bacterial staining and quantified by 
analysis with ImageJ. In all cases, TiBP-Spacer5-AMP bio-coating reduced the number of 
bacteria attached to the surface compared to uncoated control surfaces. The fold reduction 
for the number of bacteria on titanium surfaces with TiBP-Spacer5-AMP bio-coating is 
depicted in Table 4. There is a six–nine-fold reduction for S. mutans, with a 33–48-fold 
improvement noted for S. epidermidis on foil or implant surfaces, respectively, due to the 
presence of the TiBP-Spacer5-AMP bio-coating. These data suggest that the TiBP-Spacer5-
AMP bio-coating is an effective strategy to combat infections and consequential implant 
failure by reducing bacterial colonization which ultimately transform to a complex biofilm 
that can resist systemic administration of antibiotics and lead to implant failure.47 
Alternatively, the coating formed by the TiBP-Spacer5-AMP may interfere with bacterial 
attachment by forming a biomimetic surface that is less fouling than the bare titanium or 
titanium alloy surface.31 The increasing frequency of antibiotic resistant bacteria in hospital 
settings contributing to nosocomial infections and the increasing number of patients with co-
morbidities can both contribute to a diminished ability of the host to resist and clear bacteria 
at surgical sites which lead to implant failure. Whether by antimicrobial activity or reduced 
attachment, the reduction in the number of pathogenic bacterial by the TiBP-Spacer5-AMP 
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would result in improved patient outcomes. Lastly, we evaluated host cell response on 
titanium surfaces coated with the TiBP-Spacer5-AMP chimeric peptide.
3.3.3. Host cell attachment and viability—Host cell attachment and viability was 
evaluated in vitro using a fibroblast cell line (NIH/3T3) by measuring cell attachment, 
morphology/spreading, and viability response to TiBP-Spacer5-AMP coated substrates. The 
results are shown in Fig. 5 for titanium foils and those for orthopedic implants are shown in 
Fig. 6. The number of fibroblasts that attached to the TiBP-Spacer5-AMP bio-coated foils 
was not statistically different compared to an untreated control surface. However, the cells 
attached on the chimeric peptide bio-coated foil surface did demonstrate greater coverage, 
suggesting they spread more effectively compared to cells grown on untreated control 
surfaces. As expected, collagen-coated surfaces, the gold-standard used as a positive control, 
did outperform the TiBP-Spacer5-AMP chimeric peptide bio-coating. Interestingly, for 
studies with fibroblasts seeded onto titanium implant surfaces, the chimeric peptide bio-
coated surfaces showed statistically greater cell attachment and spreading properties than 
observed for the unmodified implant substrates. Additionally, the TiBP-Spacer5-AMP bio-
coated implant surfaces showed adhesion and spreading results that were statistically 
comparable to the positive collagen controls. These results suggest that bio-coating 
orthopedic medical implants with TiBP-Spacer5-AMP would result in an improved host cell 
response at the implant-tissue interface.
The MTT assay was used as a live-dead discrimination assay for fibroblasts grown on 
various surfaces. We found that cell viability on either titanium foils or implant surfaces 
treated with chimeric peptide were similar to values observed for the positive control 
collagen coated surfaces (Fig. 7), with approximately 50% greater cell viability observed 
compared to untreated surfaces.
4. Conclusion
A titanium binding, antimicrobial chimeric peptide with novel spacer design (TiBP-Spacer5-
AMP) was rationally engineered. Computational structure analysis revealed secondary 
structural features that were dependent on the length and composition of the spacer. These 
features were confirmed through direct evaluation with CD. Specifically, TiBP-Spacer5-
AMP has multiple short α-helix features with predominately irregular or random coil 
secondary structure corroborated by Ramachandran plot analysis of energy minimized 
structures and CD. The previously developed “rule induction method” was applied and 
predicted the beneficial effect of structural features induced by the spacer that resulted in 
greater antimicrobial activity. In fact, a three-fold decrease in MIC that indicates increased 
antimicrobial activity was observed against bacteria common to nosocomial implant 
infection. TiBP-Spacer5-AMP was assembled on titanium foils and orthopedic implant 
surfaces as a biomimetic coating which reduced bacterial numbers nine-fold against S. 
mutans, a bacteria common to dental implant infections, and 48-fold against S. epidermidis 
bacteria common to orthopedic implant infections. The potential of the chimeric peptide bio-
coating to promote host cell attachment was evaluated using a fibroblast cell line. On 
chimeric peptide bio-coated surfaces, the cells attached, spread and exhibited 50% greater 
viability measured by a metabolic assay compared to identical cells on bare, untreated 
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titanium surfaces. Data from the TiBP-Spacer5-AMP point to the importance of optimal 
design of the spacer between two functional domains within the chimeric peptide in order to 
optimize the function of each domain, namely binding and self-assembling onto titanium 
surfaces and the displayed antimicrobial activity on the biomaterial surface. The ability to 
create an antimicrobial bio-coating on titanium medical implants that serve to overcome 
complications associated with implant failure due to nascent infection and their eventual loss 
by infection that contributes to increasing medical costs and patient morbidity has 
interminable value.
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Refer to Web version on PubMed Central for supplementary material.
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Lowest energy structures modeled in solution for (a) TiBP-Spacer3-AMP chimeric peptide; 
(b) TiBP-Spacer5-AMP chimeric peptide; (c) Spacer3 (GGG); (d) Spacer5 (GSGGG); (e) 
AMP; (f) TiBP. The peptide backbone is represented as a ribbon to show secondary structure 
for peptides with side chains represented by full atoms. TiBP domains, spacer domains, and 
AMP domains are designated with blue-, black-, and red-shading, respectively. The. TiBP-
Spacer3-AMP (a) has an α-helix feature beginning with the AMP domain and preserved 
through Spacer3, whereas TiBP-Spacer5-AMP (b) has a shorter α-helix ends at Spacer5. 
Both functional domains, AMP (e) and TiBP (f) have α-helix secondary structure, with a 
stronger prominence in the AMP domain (color online).
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CD spectrum for TiBP-Spacer5-AMP chimeric peptide at a concentration of 50 μM in PBs, 
pH 7.4. The feature designated by the arrow indicates a greater preference for right-
circularly polarized light absorbance compared to the previously published spectrum for 
chimeric peptide with Spacer3.26 The CAPITO and Raussens methods indicates a 
predominance of irregular and random coil features in the spectrum consistent with what is 
observed in the computationally generated secondary structure for TiBP-Spacer5-AMP 
shown in Fig. 1(b).38,39
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Fluorescent microscope images (Scale Bar is 100 μm) of S. mutans bacteria on 99% pure 
titanium foils and orthopedic implant discs with TiBP-Spacer5-AMP bio-coating and bare, 
bare untreated controls. Chart depicts the percent surface coverage quantified by ImageJ of 
bacteria on the titanium surfaces.
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Fluorescent microscope images (Scale Bar is 100 μm) of S. epidermidis bacteria on 99% 
pure titanium foils and orthopedic implant discs with TiBP-Spacer5-AMP bio-coating and 
bare, bare untreated controls. Chart depicts the percent surface coverage quantified by 
ImageJ of bacteria on the titanium surfaces.
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Fluorescent images of NIH/3T3 fibroblast attachment on titanium foils: Control (no 
treatment), Collagen (200 μg/mL collagen coating positive control), or TiBP-AMP (60 μM 
TiBP-Spacer5-AMP bio-coating). Scale bar represents 500 μm for 4× images and 100 μm 
for 20× images. TiBP-Spacer5-AMP bio-coated foils had fewer fibroblasts attach compared 
to untreated control, however the fibroblast surface coverage for TiBP-Spacer5-AMP was 
greater indicating the cells spread more.
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Fluorescent images of NIH/3T3 fibroblast attachment on titanium orthopedic implants: 
Control (no treatment), Collagen (200 μg/mL collagen coating positive control), or TiBP-
AMP (60 μM TiBP-Spacer5-AMP bio-coating). Scale bar represents 500 μm for 4× images 
and 100 μm for 20× images. TiBP-Spacer5-AMP bio-coated implants showed greater cell 
attachment and spreading compared to untreated controls and attachment and spreading 
were comparable to collagen positive controls.
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NIH/3T3 fibroblast metabolism on titanium foils and implants measured by MTT assay. 
Control (no treatment), collagen (coated with 200 μg/mL collagen), TiBP-AMP (coated with 
TiBP-Spacer5-AMP at 60 μM).
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Table 1
Physical chemical properties and amino acid sequences for TiBP, AMP, and two chimeric peptides TiBP-
Spacer3-AMP and TiBP-Spacer5-AMP.
Name Sequence Spacer length MW (kDa) PI Charge GRAVY
TiBP RPRENRGRERGL N/A 1.4956 11.82 +3 −2.633
AMP LKLLKKLLKLLKKL N/A 1.6923 10.70 +6 0.500
TiBP-Spacer 3-AMP RPRENRGRERGL −GGG LKLLKKLLKLLKKL 3 3.3411 11.85 +9 −0.890
TiBP-Spacer 5-AMP RPRENRGRERGL GSGGG LKLLKKLLKLLKKL 5 3.4852 11.85 +9 −0.871
Notes: MW, molecular weight; pI, isoelectric point; GRAVY, GRand Average Value of hydropathicitY; and “−”, gap inserted for sequence 
alignment. Despite chimeric peptide similarity to one another, we observed improved antimicrobial activity with the altered amino acid 
composition of the longer peptide spacer, Spacer5.
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Table 2
“Rule Induction” method predictions of antimicrobial activity based on secondary structure features of four 
and five amino acid alpha helicity present in computationally generated structures.24 Increasing antimicrobial 
activity is associated with increasing percent of helix frequency over either a four or five amino acid average. 
The “rule induction method” predicts that TiBP-Spacer5-AMP possesses a secondary structure associated with 
antimicrobial activity to a greater extent than the secondary structure of the TiBP-Spacer3-AMP.
Peptide 4 aa α-helix frequency (%) 5 aa α-helix frequency (%)
TiBP-Spacer3-AMP 10.4 5.6
TiBP-Spacer5-AMP 17.6 8.0
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Table 3
MIC of TiBP-Spacer5-AMP, TiBP-Spacer3-AMP, and AMP alone in solution against S. mutans and S. 
epidermidis. There is a three-fold decrease in TiBP-Spacer5-AMP MIC against S. mutans.
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Table 4
Fold improvement calculated from fluorescent microscopy image analysis of S. mutans and S. epidermidis 
bacteria on titanium foil and implant surfaces with TiBP-Spacer5-AMP bio-coating, compared to bare, 
uncoated control surfaces. There is in resistance to bacteria as a result of the TiBP-Spacer5-AMP bio-coating 
on foil and implant surfaces.
Fold improvement compared to uncoated Ti surfaces
Foils Implants
TiBP-Spacer5-AMP against S. mutans 6 9
TiBP-Spacer5-AMP against S. epidermidis 33 48
J Mol Eng Mater. Author manuscript; available in PMC 2017 September 19.
